Are you Dr. Schachter?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Ks-457
Boston, MA 02215Phone+1 617-667-4460Fax+1 617-667-7919
Summary
- Dr. Steven Schachter, MD is a board certified neurologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Beth Israel Deaconess Medical Center and is a Professor of Neurology at Beth Israel Deaconess Medical Center.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1981 - 1984
University of North Carolina HospitalsInternship, Internal Medicine, 1980 - 1981
Case Western Reserve University School of MedicineClass of 1980
Certifications & Licensure
MA State Medical License 1982 - 2023- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 700 citationsVagus nerve stimulation therapy for partial-onset seizures A randomized active-control trialAdrian Handforth, Christopher M. DeGiorgio, Steven C. Schachter, Basim M. Uthman, Dean K. Naritoku
Neurology. 1998-07-01 - 335 citationsProspective Long-Term Study of Vagus Nerve Stimulation for the Treatment of Refractory SeizuresChristopher M. DeGiorgio, Steven C. Schachter, Adrian Handforth, Martin C. Salinsky, J. Thompson
Epilepsia. 2000-09-01 - 64 citationsVagus nerve stimulation reduces cardiac electrical instability assessed by quantitative T-wave alternans analysis in patients with drug-resistant focal epilepsyAndrew C. Schomer, Bruce D. Nearing, Steven C. Schachter, Richard L. Verrier
Epilepsia. 2014-12-01
Press Mentions
NIH MedTech Program Aims to Accelerate Medical Devices to Treat, Diagnose Nervous System DisordersNovember 21st, 2022
LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient over Five YearsSeptember 4th, 2018
LivaNova Launches Global Clinical Registry to Assess VNS Therapy Treatment for Drug-Resistant Epilepsy PatientsAugust 24th, 2018- Join now to see all
Grant Support
- Feasibility Of A Combined Seizure Detector-Vns SystemNational Center For Research Resources2008
- Remacemide As Monotherapy In Partial Onset SeizuresNational Center For Research Resources2000–2002
- Trial Of Gp47779 (Nhd Of Oxcarbazepine) Administered IV To InpatientsNational Center For Research Resources1999–2002
- Losigamone As Monotherapy In Treatment Of Complex Partial SeizuresNational Center For Research Resources1999–2002
- Extension Trial Of Oxcarbazepine In Patients W/ Partial SeizuresNational Center For Research Resources1999–2002
- Pregabalin OPEN Label, Follow On Safety Trial In Patients W/ EpilepsyNational Center For Research Resources1999–2000
- Pregabalin In Patient Monotherapy Trial In Patients W/ EpilepsyNational Center For Research Resources1999–2000
- Losigamone In Treatment Of Complex Childrens HospitalNational Institute Of Neurological Disorders And Stroke1998–2000
- Evaluation Of ADD On 534u87 Treatment Of Partial SeizuresNational Center For Research Resources1998–2000
- Trial Of Oxcarbazepine In Patients With Partial SeizuresNational Center For Research Resources1996–1999
- Losigamone As Monotherapy For Complex Partial SeizuresNational Institute Of Neurological Disorders And Stroke1997
- Remacemide Inpatient Seizure Evaluation TrialNational Center For Research Resources1997
- Vagus Nerve Stimulation For Adjunctive Treatment Of EpilepsyNational Center For Research Resources1996–1997
